BR112022021244A2 - Composto, e, método de tratamento de uma doença ou distúrbio - Google Patents

Composto, e, método de tratamento de uma doença ou distúrbio

Info

Publication number
BR112022021244A2
BR112022021244A2 BR112022021244A BR112022021244A BR112022021244A2 BR 112022021244 A2 BR112022021244 A2 BR 112022021244A2 BR 112022021244 A BR112022021244 A BR 112022021244A BR 112022021244 A BR112022021244 A BR 112022021244A BR 112022021244 A2 BR112022021244 A2 BR 112022021244A2
Authority
BR
Brazil
Prior art keywords
treatment
disorder
disease
compound
compounds
Prior art date
Application number
BR112022021244A
Other languages
English (en)
Portuguese (pt)
Inventor
Louise Lucas Cathy
Charles Ray Nicholas
Mary Seward Eileen
Hynd George
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of BR112022021244A2 publication Critical patent/BR112022021244A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022021244A 2020-04-22 2021-04-22 Composto, e, método de tratamento de uma doença ou distúrbio BR112022021244A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005863.2A GB202005863D0 (en) 2020-04-22 2020-04-22 Therapeutic compounds
PCT/GB2021/050973 WO2021214470A1 (en) 2020-04-22 2021-04-22 Tetrahydroisoquinoline compounds as nrf2 activators

Publications (1)

Publication Number Publication Date
BR112022021244A2 true BR112022021244A2 (pt) 2022-12-06

Family

ID=70860156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021244A BR112022021244A2 (pt) 2020-04-22 2021-04-22 Composto, e, método de tratamento de uma doença ou distúrbio

Country Status (16)

Country Link
US (1) US20230167084A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139294B1 (cg-RX-API-DMAC7.html)
JP (1) JP7679400B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004720A (cg-RX-API-DMAC7.html)
CN (1) CN115667243B (cg-RX-API-DMAC7.html)
AR (1) AR121912A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021259366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174361A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032247T3 (cg-RX-API-DMAC7.html)
GB (1) GB202005863D0 (cg-RX-API-DMAC7.html)
IL (1) IL297434A (cg-RX-API-DMAC7.html)
MX (1) MX2022013398A (cg-RX-API-DMAC7.html)
PH (1) PH12022552775A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214470A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211465B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207469A (en) * 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds
CR20240325A (es) * 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2
WO2025237912A1 (en) 2024-05-13 2025-11-20 Astrazeneca Ab Keap1 inhibitors for use in the treatment of bronchiectasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
KR20180017038A (ko) * 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
MY207469A (en) 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds

Also Published As

Publication number Publication date
AR121912A1 (es) 2022-07-20
JP2023524206A (ja) 2023-06-09
EP4139294B1 (en) 2025-04-09
EP4139294A1 (en) 2023-03-01
JP7679400B2 (ja) 2025-05-19
CN115667243A (zh) 2023-01-31
KR20230004720A (ko) 2023-01-06
CA3174361A1 (en) 2021-10-28
MX2022013398A (es) 2022-12-13
US20230167084A1 (en) 2023-06-01
ZA202211465B (en) 2025-06-25
AU2021259366A1 (en) 2022-11-10
GB202005863D0 (en) 2020-06-03
WO2021214470A1 (en) 2021-10-28
PH12022552775A1 (en) 2024-03-25
CN115667243B (zh) 2025-01-07
IL297434A (en) 2022-12-01
ES3032247T3 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
BR112022021370A2 (pt) Composto, e, método de tratamento de uma doença ou distúrbio
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112022023271A2 (pt) Compostos
BR112022018600A2 (pt) Compostos, composição farmacêutica, método de tratamento de uma doença e combinação
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
BR112022020798A2 (pt) Compostos tricíclicos como inibidores de nlrp3
BR112019007039A2 (pt) pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112022021881A2 (pt) Novos compostos de triazinoindol
BR112022024045A2 (pt) Moduladores il-17a
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
BR112021021477A2 (pt) Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112022001308A2 (pt) Inibidores tricíclicos de kars dependentes de akr1c3
MX2021004566A (es) Compuestos terapeuticos.
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112022025005A2 (pt) Formação de imagem e terapia dirigidas por granzima b
BR112017022757A2 (pt) derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap)
BR112023017434A2 (pt) Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]